New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:48 EDTPCYC, ABTPharmacyclics shares have 90% upside potential, says Deutsche Bank
Deutsche Bank believes shares of Pharmacyclics (PCYC) have 90% upside potential over the next 12 months following the recent pullback. Deutsche attributes to the recent pullback to fears around Abbott's (ABT) data for ABT199 at ASCO and weekly scripts that came in lower than some investor expectations. The firm has a Buy rating on Pharmacyclics with a $180 price target.
News For PCYC;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 28, 2015
07:43 EDTABTMead Johnson pushing for changes to WIC program, WSJ reports
The law authorizing the $6B per year WIC program providing food vouchers to women who are pregnant or have young children is up for renewal this year and formula makers, led by top U.S. maker Mead Johnson (MJN), are pushing for change, said The Wall Street Journal. Growth in the program has made it a money-losing venture for baby formula makers who essentially make no profit off formula sold to states as part of the program and Mead Johnson is pushing for changing eligibility requirements, thereby limiting or even shrinking the pool of recipients, the report noted. Other U.S. infant formula makers include Abbott (ABT) and Nestle (NSRGY). Reference Link
April 23, 2015
10:02 EDTPCYCAbbVie says communication with Johnson & Johnson has been 'very positive'
Subscribe for More Information
09:20 EDTPCYCCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
09:07 EDTPCYCAbbVie says remains on track to complete Pharmacyclics acquisition in Q2
April 22, 2015
14:08 EDTPCYCEarnings Watch: AbbVie's Humira sales will be focus for Q1
Subscribe for More Information
09:26 EDTABTAbbott sees flat growth in Molecular Diagnostics business in Q2
Sees mid-single digit growth for Global Diagnostics growth in Q2. Sees low single digit growth for Global Vascular in Q2. Expects similar double digit growth in EPD in Q2.
09:21 EDTABTAbbott sees FY15 revenue growth to be in low single digits, consensus $20.71B
Subscribe for More Information
09:20 EDTABTAbbott sees Q2 EPS 49c-51c, consensus 52c
Subscribe for More Information
07:48 EDTABTAbbott reports Q1 Nutrition sales up 6.3% to $1.67B
Subscribe for More Information
07:46 EDTABTAbbott backs FY15 adjusted EPS $2.10-$2.20, consensus $2.14
Subscribe for More Information
07:45 EDTABTAbbott reports Q1 adjusted EPS 47c, consensus 42c
Subscribe for More Information
April 21, 2015
15:28 EDTABTNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Coca-Cola (KO), consensus 42c... Boeing (BA), consensus $1.81... McDonald's (MCD), consensus $1.06... EMC (EMC), consensus 36c... Abbott Laboratories (ABT), consensus 42c... Thermo Fisher Scientific (TMO), consensus $1.61... Bank of New York Mellon (BK), consensus 59c... TE Connectivity (TEL), consensus $1.01... T. Rowe Price Group (TROW), consensus $1.14... St. Jude Medical (STJ), consensus 91c... Amphenol (APH), consensus 56c... Nielsen (NLSN), consensus 47c... Citizens Financial Group (CFG), consensus 34c... Autoliv (ALV), consensus $1.31... D.R. Horton (DHI), consensus 38c... Westinghouse Air Brake Technologies (WAB), consensus 95c... Huntington Bancshares (HBAN), consensus 19c... SEI Investments (SEIC), consensus 49c... AutoNation (AN), consensus 89c... Gentex (GNTX), consensus 25c... Ryder System (R), consensus $1.00... Owens Corning (OC), consensus 13c... NuStar Energy (NS), consensus 58c... Six Flags (SIX), consensus (67c)... Tupperware Brands (TUP), consensus 98c... MarketAxess Holdings (MKTX), consensus 64c... Lithia Motors (LAD), consensus $1.22... Knight Transportation (KNX), consensus 31c... Evercore Partners (EVR), consensus 58c... Potlatch (PCH), consensus 19c... Natus Medical (BABY), consensus 29c... AZZ (AZZ), consensus 59c... United Community Banks (UCBI), consensus 29c... Sonus Networks (SONS), consensus (31c)... Angie's List (ANGI), consensus 0c... Pacific Premier Bancorp (PPBI), consensus 27c.
April 20, 2015
14:32 EDTPCYCPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information
09:05 EDTPCYCPharmacyclics reports positive data suggesting ibrutinib is an effective option
Ibrutinib data presented yesterday by Pharmacyclics at the American Association for Cancer Research, or AACR, Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft mice. These early, pre-clinical data show ibrutinib was associated with potent anti-fibrotic activity and longer survival in the treated mice. PDAC is a type of pancreatic cancer that is typically characterized by a fibro-inflammatory reaction, which makes PDAC a difficult disease to treat with current therapies. These data were also published in the April 15th edition of Cancer Research. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech.
08:47 EDTPCYCPharmacyclics announces positive results from PCYC-1102 study
Pharmacyclics announced that IMBRUVICA follow-up data in treatment-naive, or TN, and relapsed/refractory patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, or CLL and SLL respectively, demonstrated that, with up to 45 months of follow-up, the 94 patients who received IMBRUVICA 420 mg experienced a 91% overall response rate, or ORR, and 14% of all patients achieved a complete response. These data are an analysis of outcomes from the Phase I/IIb study, or PCYC-1102, and the ongoing extension study and were presented in an oral presentation at the American Association of Cancer Research.
April 17, 2015
16:50 EDTPCYCAbbVie extends exchange offer to acquire Pharmacyclics
Subscribe for More Information
April 15, 2015
07:41 EDTABTEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
09:06 EDTABTAbbott and Sekisui announce collaboration for coagulation testing
Abbott and Sekisui announce an agreement to offer coagulation testing solutions for laboratories worldwide. Coagulation tests measure a person's blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots. Under the agreement, Abbott will be the exclusive distributor of Sekisui's new CP3000 coagulation instrument in the United States, Europe and other regions that recognize CE Mark.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use